1-6 of 6
Timothy M Schmidt
Close
Sort by
Journal Articles

Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review

Karun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal, Timothy M Schmidt, Rafael Fonseca, Doug Sborov, Meera Mohan, Hira Mian, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin
Journal: Blood
Blood (2023) 142 (Supplement 1): 3363.
https://doi.org/10.1182/blood-2023-180271
Published: 2023
Journal Articles

Agent myeloma has a new weapon from (ch1)Q

Timothy M. Schmidt, Lawrence H. Boise
Journal: Blood
Blood (2022) 139 (13): 1927–1928.
https://doi.org/10.1182/blood.2021015336
Published: 2022
Journal Articles

Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy

Susan Bal, Saurabh Chhabra, Natalie S. Callander, Eva Medvedova, Bhagirathbhai Dholaria, Rebecca W. Silbermann, Kelly N. Godby, Binod Dhakal, Smith Giri, Anita d'Souza, Timothy M. Schmidt, Aric C. Hall, Pamela Hardwick, Robert F. Cornell, Parameswaran Hari, Luciano J. Costa
Journal: Blood
Blood (2021) 138 (Supplement 1): 483.
https://doi.org/10.1182/blood-2021-145533
Published: 2021
Journal Articles

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial

Luciano J. Costa, Saurabh Chhabra, Natalie S. Callander, Eva Medvedova, Bhagirathbhai Dholaria, Rebecca W. Silbermann, Kelly N. Godby, Binod Dhakal, Susan Bal, Smith Giri, Anita d'Souza, Timothy M. Schmidt, Aric C. Hall, Pamela Hardwick, Robert F. Cornell, Parameswaran Hari
Journal: Blood
Blood (2021) 138 (Supplement 1): 481.
https://doi.org/10.1182/blood-2021-145494
Published: 2021
Journal Articles

Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone

Timothy M. Schmidt, MD, Nisha Joseph, MD, Levani Odikadze, MD MPH, Leonard Heffner, MD, Craig C Hofmeister, MD MPH, Madhav V Dhodapkar, MD, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD, David L. Jaye, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH, Jonathan L Kaufman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3241.
https://doi.org/10.1182/blood-2018-99-112216
Published: 2018
Journal Articles

Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy

Levani Odikadze, MD MPH, Nisha Joseph, MD, Timothy M. Schmidt, MD, Leonard Heffner, MD, Craig C Hofmeister, MD MPH, Madhav V Dhodapkar, MD, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD, David L. Jaye, MD, Sagar Lonial, MD, Ajay K Nooka, MD MPH, Jonathan L Kaufman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1884.
https://doi.org/10.1182/blood-2018-99-114368
Published: 2018